BioNexus Gene Lab Corp Common stock (BGLC) — Capital Reinvestment Ratio
Latest as of December 2022:
0.04x
BioNexus Gene Lab Corp Common stock (BGLC) has a Capital Reinvestment Ratio of 0.04x as of December 2022, meaning it reinvests 0% of its operating cash flow ($474.47K) in capital expenditures ($17.03K). See BioNexus Gene Lab Corp Common stock free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.04x
Capex / Operating Cash Flow
Operating Cash Flow
$474.47K
USD
Capital Expenditures
$17.03K
USD
Data as of
Dec 2022
Most recent filing
BioNexus Gene Lab Corp Common stock Capital Reinvestment Ratio (2017–2022)
This chart tracks BioNexus Gene Lab Corp Common stock's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for BioNexus Gene Lab Corp Common stock (2017–2022)
Year-by-year Capital Reinvestment Ratio for BioNexus Gene Lab Corp Common stock from 2017 to 2022. For live market cap and broader valuation context, see BGLC company net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.10x | $544.03K | $54.17K | ▼ -71.2% |
| 2021 | 0.35x | $9.16K | $3.16K | ▼ -54.8% |
| 2020 | 0.76x | $552.68K | $421.62K | ▼ -13.4% |
| 2017 | 0.88x | $357.22K | $314.82K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow